Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Firsocostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA known ✓ | Q13085 | 18/20 | 0.89 |
| ▸ | ACACB known ✓ | O00763 | 13/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Firsocostat SCHEMBL29351205 | 1.00 | ACACA (0.89) | ACACAACACB | |
| Firsocostat SCHEMBL14945041 | 1.00 | ACACA (0.89) | ACACAACACB | |
| Firsocostat SCHEMBL24849124 | 1.00 | ACACA (0.89) | ACACAACACB | |
| Firsocostat SCHEMBL29539821 | 1.00 | ACACA (0.89) | ACACAACACB | |
| SCHEMBL14936101 | 0.95 | ACACA (0.81) | ACACAACACB | |
| SCHEMBL29453865 | 0.95 | ACACA (0.81) | ACACAACACB | |
| SCHEMBL14936100 | 0.95 | ACACA (0.81) | ACACAACACB | |
| SCHEMBL20637789 | 0.95 | ACACA (0.81) | ACACAACACB | |
| SCHEMBL14935870 | 0.95 | ACACA (0.80) | ACACAACACB | |
| SCHEMBL20637794 | 0.95 | ACACA (0.80) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364795-A2 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | Gilead Apollo, LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11963961-B2 | Combination therapy comprising an ACC inhibitor | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3423456-B1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20220347190-A1 | TREATMENT COMPRISING FXR AGONISTS | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| CN-110431143-B | Heteroaryl pyrimidone derivatives, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-4031137-A1 | TREATMENT COMPRISING FXR AGONISTS | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| EP-2776038-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | J.P. LAWSON CONSULTING LLC | 2017-09-21 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-9453026-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2776038-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACA 1/4885ACACB 2/4885 |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | ACACA 1/4885ACACB 2/4885 |
| US-20220347190-A1 | TREATMENT COMPRISING FXR AGONISTS | NR1H4, FXR1, FXR2 | ACACA 173/4885ACACB 334/4885 |
| US-11963961-B2 | Combination therapy comprising an ACC inhibitor | ACACB, ACACA, LIPC | ACACA 2/4885ACACB 1/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACA 1/4885ACACB 2/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACA 1/4885ACACB 2/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACA 1/4885ACACB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.